Grace Therapeutics Receives FDA Meeting Minutes From Type A Meeting; FDA Confirms No Clinical Safety Or Efficacy Deficiencies
Grace Therapeutics, Inc GRCE
$2.08
▲ +0.48%
(+$0.01)
🎈 Low Float
🗓️ Earnings Next Week
Open
$2.10
Prev Close
$2.07
Day Range
$2.03 – $2.17
52W Range
$1.79 – $5.18
Market Cap
$33.85M
Beta
0.41
EPS (TTM)
$-0.48
📋 Company Profile
| Industry | Pharmaceuticals |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2013-03-07 |
| Shares Out. | 16,270,000 |
| Website | gracetx.com/ ↗ |
| Phone | 16093221602 |
| Employees | 5 |
| Net Income | -$1.2M |
| Total Assets | $66.7M |
| Total Liabilities | $2.8M |
| Equity | $63.9M |
About Grace Therapeutics, Inc
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
Grace Therapeutics, Inc is a publicly traded company under the ticker symbol GRCE on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-07-01)